Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc is making significant strides in addressing healthcare costs associated with challenging cancer treatments, particularly through its CNSide product, which may reduce leptomeningeal metastases-related costs by approximately 40%. The receipt of an $18 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to study leptomeningeal metastases further supports the company's strategic development and resource allocation. Additionally, positive FDA Type B feedback regarding accelerated approval for key drug candidates enhances market confidence in Plus Therapeutics’ potential for successful commercialization and reimbursement outcomes.

Bears say

The financial analysis indicates concerns regarding Plus Therapeutics's stock, primarily driven by its planned 1-for-25 reverse stock split, which typically reflects underlying capital market difficulties in small-cap biotechnology companies and may impact trading liquidity. Furthermore, the company reported an operating loss of $15.3 million and a net loss of $22.4 million for the full year 2025, even as it ended the year with $13.1 million in cash and investments, highlighting significant financial strains. Lastly, potential risks such as failure to achieve clinical trial success, secure regulatory approvals, and navigate competitive pressures further contribute to a negative outlook for the company's future financial stability and growth.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.